Rutin / AGEs Cancer Research Results

RT, Rutin: Click to Expand ⟱
Features:
Rutin, a Quercetin Glycoside
Rutin, a natural flavonoid glycoside found in many plants like buckwheat, citrus fruits, and apples, has shown promising neuroprotective and anticancer properties.
Rutin is a flavonoid glycoside composed of quercetin bound to the disaccharide rutinose. It is widely found in buckwheat, citrus fruits, apples, and tea. In cancer models, rutin exhibits antioxidant, anti-inflammatory, anti-proliferative, and pro-apoptotic effects. Because it is glycosylated, rutin itself has relatively low cellular permeability; many biological effects are mediated after intestinal hydrolysis to quercetin and subsequent phase-II metabolites. Mechanistically, rutin is most consistently associated with suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, redox regulation (Nrf2/ROS balance), inhibition of angiogenesis (VEGF), and induction of cell-cycle arrest and apoptosis in preclinical systems. Effects are model-dependent and often concentration-dependent, with antioxidant behavior dominating in normal tissue contexts and context-dependent pro-oxidant effects described in some tumor settings.
-Scavenges free radicals, reduces oxidative stress
-Inhibits pro-inflammatory cytokines like IL-1β, TNF-α, and reduces activation of NF-κB.
-Inhibition of Aβ Aggregation (AD)
-Mild inhibitory effects on acetylcholinesterase (AChE), helping enhance cholinergic function.
-May upregulate BDNF expression

Cancer:
-Induces cell cycle arrest in G2/M phase.
-Inhibits VEGF, Suppresses MMP-2 and MMP-9
-Inhibits PI3K/Akt/mTOR, MAPK, and NF-κB signaling pathways.
-Enhances sensitivity to Chemotherapy drugs like doxorubicin and cisplatin

Rutin has poor oral bioavailability, but this can be improved with nanoformulations or co-administration with absorption enhancers like piperine or quercetin.


Cancer Pathway Table: Rutin

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory / survival signaling NF-κB ↓; COX-2, cytokines ↓ (reported) Inflammatory tone ↓ R, G Anti-inflammatory / anti-survival Frequently reported mechanism; contributes to reduced tumor-promoting inflammation and survival signaling.
2 PI3K → AKT → mTOR axis PI3K/AKT ↓; proliferation ↓ (model-dependent) ↔ R, G Growth signaling suppression Observed in several tumor models; often secondary to upstream redox and inflammatory modulation.
3 Cell-cycle regulation (Cyclins/CDKs; G1 or G2/M arrest) Cell-cycle arrest ↑ (reported) ↔ G Cytostasis Associated with reduced Cyclin D1/CDK expression; typically downstream of survival pathway inhibition.
4 Intrinsic apoptosis (mitochondrial pathway) Bax ↑; Bcl-2 ↓; caspases ↑ (reported) Minimal activation at lower exposure G Apoptotic execution Apoptosis induction frequently reported in vitro; magnitude depends on achievable intracellular concentration.
5 ROS modulation (biphasic redox behavior) ROS ↑ in some tumor contexts; apoptosis ↑ ROS ↓ (antioxidant protection) P, R Redox modulation Rutin is classically antioxidant but may promote oxidative stress in tumor cells under certain conditions (dose/metal-dependent).
6 Nrf2 / ARE antioxidant response Context-dependent modulation Nrf2 ↑; antioxidant enzymes ↑ R, G Redox buffering Common polyphenol signature; may protect normal tissue from oxidative injury.
7 MAPK pathways (ERK / JNK / p38) Stress-MAPK modulation (context-dependent) ↔ P, R, G Signal reprogramming JNK/p38 activation reported in apoptosis contexts; ERK modulation varies by model.
8 Angiogenesis signaling (VEGF) VEGF ↓; angiogenic outputs ↓ (reported) ↔ G Anti-angiogenic support Often secondary to NF-κB and PI3K suppression.
9 Invasion / metastasis (MMPs / EMT) MMP2/MMP9 ↓; migration ↓ (reported) ↔ G Anti-invasive phenotype Typically downstream of inflammatory and MAPK modulation.
10 Bioavailability constraint (glycoside → quercetin metabolism) Systemic exposure mainly as metabolites — — Translation constraint Rutin has limited direct cellular uptake; many effects likely mediated after conversion to quercetin and phase-II metabolites.

TSF: P = 0–30 min (rapid redox interactions), R = 30 min–3 hr (acute signaling shifts), G = >3 hr (gene-regulatory adaptation and phenotype outcomes).



Alzheimer’s Disease (AD) Summary — Rutin

Rutin has been studied in preclinical neurodegeneration models for its antioxidant, anti-inflammatory, and mitochondrial-protective properties. It is reported to modulate Nrf2 signaling, suppress NF-κB–mediated neuroinflammation, reduce oxidative stress, and attenuate amyloid-β–induced neuronal injury in experimental systems. Many effects may be mediated after hydrolysis to quercetin. Human clinical evidence remains limited.


Alzheimer’s Disease Table: Rutin

Rank Pathway / Axis AD / Neurodegeneration Context Normal Brain Context TSF Primary Effect Notes / Interpretation
1 Nrf2 / ARE antioxidant response Nrf2 ↑; HO-1 ↑; GSH ↑; oxidative damage ↓ (reported) Redox homeostasis support R, G Antioxidant neuroprotection Consistent polyphenol signature; reduces lipid peroxidation and ROS markers in AD models.
2 NF-κB / neuroinflammation Microglial activation ↓; TNF-α / IL-1β ↓ (reported) Inflammatory tone moderation R, G Anti-inflammatory modulation Neuroinflammation is a core AD driver; rutin shows suppression in animal models.
3 Amyloid-β toxicity modulation Aβ-induced ROS ↓; neuronal apoptosis ↓ (reported) ↔ G Anti-amyloid support Evidence mainly from in vitro and rodent models; not confirmed clinically.
4 Mitochondrial protection ΔΨm stabilization; ATP preservation (reported) Mitochondrial resilience R Bioenergetic protection Opposes mitochondrial dysfunction induced by oxidative stress.
5 MAPK (JNK / p38 stress signaling) Stress-MAPK suppression (reported) ↔ P, R Stress signaling reduction JNK/p38 activation linked to neuronal apoptosis; suppression reported in models.
6 Cholinergic signaling (reported in some models) AChE activity ↓ (reported) ↔ G Cognitive support (model-based) Evidence limited; magnitude smaller than pharmaceutical AChE inhibitors.
7 BBB penetration (metabolite-driven) Effects likely via quercetin metabolites Systemic metabolism required — Translation constraint Parent rutin has limited direct brain penetration; hydrolysis/metabolism important.
8 Clinical evidence Limited human AD trials — — Evidence constraint Most data preclinical; not established as AD therapy.

TSF: P = 0–30 min (early signaling modulation), R = 30 min–3 hr (stress-response shifts), G = >3 hr (gene-regulatory and neuroprotective outcomes).



AGEs, Advanced Glycation End Products: Click to Expand ⟱
Source:
Type:
Advanced Glycation End Products (AGEs) are highly reactive compounds formed when proteins or lipids become non-enzymatically glycated after exposure to sugars. AGEs accumulate with age and are implicated in various chronic diseases—including Alzheimer’s disease (AD).
-AGEs bind to Aβ peptides, increasing aggregation and plaque stability.
-AGEs activate kinases like GSK-3β and p38 MAPK, promoting tau phosphorylation.
-Human brains with AD show increased AGE-modified proteins and elevated RAGE expression.
-Blocking RAGE or reducing AGEs slows cognitive decline and pathology in mice.

Strategies to Reduce AGE Burden
-Low-AGE cooking (steaming, boiling), Mediterranean diet
- reduce processed meats, sugary baked goods, and fried foods.
Scientific Papers found: Click to Expand⟱
7953- BuckWS,  RT,    Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid
- Review, Nor, NA
*GastroP↑, *hepatoP↑, *AntiDiabetic↑, *Inflam↓, *BioAv↓, *LDL↓, *Fenton↓, *AGEs↓, *GSH↑, *Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Fenton↓, 1,   GSH↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   hepatoP↑, 1,  
Total Targets: 10

Scientific Paper Hit Count for: AGEs, Advanced Glycation End Products
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:143  Target#:1375  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page